New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

The Company will feature a poster, number 783-P, titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist ... approach to GLP-1 titration and dosing, including ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to ... JAMA Psychiatry – compared weekly injections with a low dose of semaglutide (0.25mg) to placebo over a nine-week period ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

The American Medical Association's House of Delegates passed an Endocrine Society resolution that aims to improve access to ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action, cardioprotective effects in models of ischemia-reperfusion injury ...

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...